Latest / The Best of the Money Show / Government and pharma industry unite to tackle manufacturing crisis
Transcript
- 0:00Speaker 1: Well, Business Live reporting this evening, President Surama Posa establishing
- 0:03Speaker 1: a government business task force. It'll try and manage the
- 0:07Speaker 1: problem of whether drugs used by the health department should
- 0:09Speaker 1: be made here. Our pharmaceutical industry, you can imagine their view.
- 0:14Speaker 1: South Africa's government should buy local. The health department should
- 0:17Speaker 1: buy local. If I were there, that would be mine too.
- 0:19Speaker 1: But the health department says it has to ensure value
- 0:22Speaker 1: for money. It'll look for the cheapest drugs. And in
- 0:25Speaker 1: a volume space, you can imagine why that might be.
- 0:28Speaker 2: Dr.
- 0:28Speaker 1: Stavros Nikolaou, is the chair of the pharmaceutical industry group Farmisa. Stavros,
- 0:34Speaker 1: good evening. Good to talk to you again. Obviously, the
- 0:36Speaker 1: health department would be a major client for you. Are
- 0:39Speaker 1: they not buying local at the moment?
- 0:42Speaker 2: Stephen, firstly, good evening to you and the viewers. And
- 0:45Speaker 2: thanks very much for having me back on your show.
- 0:48Speaker 2: I'm in fact representing the PTG, which represents the entirety
- 0:54Speaker 2: of the pharmaceutical industry in South Africa this evening. That
- 0:58Speaker 2: includes importers and local producers. It also includes the multinationals
- 1:04Speaker 2: that are R & D- based companies. Now, at the core
- 1:09Speaker 2: of the issue here is that the pharmaceutical sector presents
- 1:14Speaker 2: a real industrialization opportunity for our country. There are not
- 1:20Speaker 2: too many sectors that I think we can industrialize and
- 1:25Speaker 2: turn into globally competitive sectors. at this point in time.
- 1:30Speaker 2: I know there's the automotive sector and I'm excluding things
- 1:35Speaker 2: outside of commodities and minerals. So at a manufacturing level,
- 1:38Speaker 2: there are not many sectors that we can say hand
- 1:42Speaker 2: on heart are globally competitive. Pharmaceuticals is interesting because Africa
- 1:47Speaker 2: has the most disproportionate disease burden and per capita consumes
- 1:55Speaker 2: a disproportionate amount of pharmaceuticals. So it presents certainly at
- 2:01Speaker 2: a volume level, or if you were to aggregate volumes
- 2:04Speaker 2: on the continent, it presents an opportunity. Pharmaceuticals have also
- 2:09Speaker 2: been identified as a sector for, or one of the
- 2:13Speaker 2: key sectors for industrialization in our country. Now, having given
- 2:17Speaker 2: that background, let me answer your question. And again, at
- 2:23Speaker 2: the core of what you're asking is any country should
- 2:28Speaker 2: look at what constitutes best value for money when they
- 2:32Speaker 2: buy their pharmaceutical products and their vaccines. Best value for
- 2:38Speaker 2: money doesn't necessarily mean the cheapest. It means what is
- 2:45Speaker 2: going to give you the best economic value, both to
- 2:50Speaker 2: the fiscus, and more broadly to the country. So let
- 2:54Speaker 2: me give you an example. I mean, if you were
- 2:56Speaker 2: buying an antiretroviral for 10 Rand, I'm even making up
- 3:00Speaker 2: these numbers, and the imported product was 9 Rand and
- 3:05Speaker 2: the locally produced product was 10 Rand, and you're buying
- 3:08Speaker 2: a million units, we might say that that is a
- 3:11Speaker 2: good procurement decision if you buy the 9 Rand product
- 3:14Speaker 2: because you've saved yourself a million Rand. However, If you
- 3:19Speaker 2: are losing three rand out of that 10 rand, which
- 3:22Speaker 2: is roughly what the case is, by not manufacturing locally
- 3:27Speaker 2: and not getting the multiplier economic impact into the economy,
- 3:31Speaker 2: you're actually minus two rand or two million rand worse
- 3:35Speaker 2: off in the example that I've cited. So one should
- 3:39Speaker 2: look at this from the perspective of what constitutes best
- 3:43Speaker 2: value for money for the country and not necessarily what
- 3:46Speaker 2: is the cheapest value. Now, having said that, I should
- 3:50Speaker 2: also clarify that producing local doesn't necessarily mean that it's
- 3:55Speaker 2: the most expensive either. There are many cases where locally
- 3:59Speaker 2: produced products trump the prices of imported products. But I
- 4:03Speaker 2: guess where you want to get this to is you
- 4:06Speaker 2: want to achieve an industry that is competitive, that's resilient,
- 4:12Speaker 2: is sustainable, and above all, can respond to the needs
- 4:16Speaker 2: and demands of of the local populace and the citizens
- 4:21Speaker 2: of the country.
- 4:22Speaker 1: So I get all of that, and I get that
- 4:24Speaker 1: government should play a role in stimulating local industry. For
- 4:27Speaker 1: the patient, it is really about making sure there are
- 4:30Speaker 1: enough drugs available and that the health department has a
- 4:33Speaker 1: big enough budget to get those drugs. Now, if you
- 4:35Speaker 1: were to say to a patient for, let's just say,
- 4:38Speaker 1: with antiretroviral drugs because they save lives, it would be
- 4:42Speaker 1: an awful thing. And I know this does not happen.
- 4:45Speaker 1: But it would be an awful thing to say, I'm sorry,
- 4:47Speaker 1: you can't get it because we didn't have enough money
- 4:49Speaker 1: to buy enough. So you have to get around that problem.
- 4:52Speaker 1: And this takes us really to how big is the
- 4:55Speaker 1: price discrepancy between the drugs produced here and the drugs
- 5:00Speaker 1: that may be procured from other countries?
- 5:03Speaker 2: So let's stick to ARV symmetry on that topic. If
- 5:09Speaker 2: one analyzes the current antiretroviral contract, there are imported products
- 5:17Speaker 2: that are more expensive than the locally produced ones. Of course,
- 5:22Speaker 2: the Department of Health do this because they need to de-risk.
- 5:26Speaker 2: They need multiple supplies. So I guess the best way
- 5:32Speaker 2: to look at this is to say it's far more
- 5:37Speaker 2: expensive to have a patient that cannot get medicine at
- 5:41Speaker 2: all then a patient where the state has played slightly more.
- 5:46Speaker 2: So if you take it down to its lowest sort
- 5:50Speaker 2: of denominator, what you should aim to achieve is competitive
- 5:55Speaker 2: pricing and sustainability in supply. And we're often not getting
- 6:02Speaker 2: that at the moment. It's not just a South African phenomenon.
- 6:06Speaker 2: It's a global phenomenon where supply chains are, are under
- 6:12Speaker 2: strain at the moment. There's been a disruption of global
- 6:15Speaker 2: supply chains. Prices have gone up significantly. A lot of
- 6:20Speaker 2: the ingredients that go into producing pharmaceutical products are derived
- 6:25Speaker 2: from oil. So you are seeing a general disruption in
- 6:29Speaker 2: global supply chains and linkages. And the best way to
- 6:33Speaker 2: safeguard that, as we saw during COVID, is you need
- 6:37Speaker 2: to have a competitive and resilient domestic industry. And that's
- 6:41Speaker 2: what this task force aims to achieve. I think if
- 6:43Speaker 2: you were to ask me what is the ambition or
- 6:46Speaker 2: the vision, it's to establish a competitive, resilient, sustainable pharmaceutical
- 6:52Speaker 2: industry that can provide for the needs of its citizens. Dr.
- 6:56Speaker 1: Stavros Nikolaou, thank you so much. Speaking as the chair
- 6:58Speaker 1: of the Pharmaceutical Task Group, so much more to go into.
- 7:02Speaker 1: It's a really interesting conversation. Stavros, thank